SYNH — Syneos Health Share Price
Last trade - 00:00- $4.46bn
- $7.08bn
- $5.39bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.44 | ||
| PEG Ratio (f) | 0.94 | ||
| EPS Growth (f) | 13.85% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.27 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 15.2 | ||
| Price to Sales | 0.81 | ||
| EV to EBITDA | 12.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.51% | ||
| Return on Equity | 4.39% | ||
| Operating Margin | 5.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,390.12 | 4,675.81 | 4,415.78 | 5,212.97 | 5,393.08 | 5,144.07 | 5,203.97 | 15.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -7.71 | +168.26 | +26.72 | +4.71 | +25.73 | +12.12 | +15.02 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
Directors
- John Dineen CHM (58)
- Alistair Macdonald CEO (51)
- Jason Meggs CFO (45)
- Paul Colvin CEX (51)
- Michelle Keefe CEX (54)
- Lisa Van Capelle CHO
- Donna Kralowetz SVF (50)
- Jonathan Olefson GCN (45)
- Michael Brooks OTH
- Todd Abbrecht IND (52)
- Barbara Bodem IND
- Bernadette Connaughton IND (62)
- Linda Harty IND (61)
- William Klitgaard IND (68)
- Kenneth Meyers IND (59)
- Matthew Monaghan IND (53)
- David Wilkes IND
- Alfonso Zulueta IND
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- August 13th, 2010
- Public Since
- November 7th, 2014
- No. of Shareholders
- 20
- No. of Employees
- 28,768
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 103,647,164
- Address
- 1030 Sync Street, MORRISVILLE, 27560
- Web
- https://www.syneoshealth.com/
- Phone
- +1 9198769300
- Contact
- Ronnie Speight
- Auditors
- Deloitte & Touche LLP
Latest News for SYNH
Upcoming Events for SYNH
Syneos Health Inc Annual Shareholders Meeting
Q2 2023 Syneos Health Inc Earnings Release
Q3 2023 Syneos Health Inc Earnings Release
Similar to SYNH
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:21 UTC, shares in Syneos Health are trading at $42.38. This share price information is delayed by 15 minutes.
Shares in Syneos Health last closed at $42.38 and the price had moved by -44.01% over the past 365 days. In terms of relative price strength the Syneos Health share price has underperformed the S&P500 Index by -51.93% over the past year.
The overall consensus recommendation for Syneos Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Syneos Health does not currently pay a dividend.
Syneos Health does not currently pay a dividend.
Syneos Health does not currently pay a dividend.
To buy shares in Syneos Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $42.38, shares in Syneos Health had a market capitalisation of $4.41bn.
Here are the trading details for Syneos Health:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SYNH
Based on an overall assessment of its quality, value and momentum Syneos Health is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Syneos Health is $42.43. That is 0.12% above the last closing price of $42.38.
Analysts covering Syneos Health currently have a consensus Earnings Per Share (EPS) forecast of $3.42 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syneos Health. Over the past six months, its share price has outperformed the S&P500 Index by +4.42%.
As of the last closing price of $42.38, shares in Syneos Health were trading +9.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Syneos Health PE ratio based on its reported earnings over the past 12 months is 11.44. The shares last closed at $42.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Syneos Health's management team is headed by:
- John Dineen - CHM
- Alistair Macdonald - CEO
- Jason Meggs - CFO
- Paul Colvin - CEX
- Michelle Keefe - CEX
- Lisa Van Capelle - CHO
- Donna Kralowetz - SVF
- Jonathan Olefson - GCN
- Michael Brooks - OTH
- Todd Abbrecht - IND
- Barbara Bodem - IND
- Bernadette Connaughton - IND
- Linda Harty - IND
- William Klitgaard - IND
- Kenneth Meyers - IND
- Matthew Monaghan - IND
- David Wilkes - IND
- Alfonso Zulueta - IND